Anticipating and minimizing drug interactions in a drug discovery and development setting: An industrial perspective

Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges

Volumn , Issue , 2010, Pages 585-624

  Vuppugalla, Ragini ^a   Kim, Sean ^a   Zvyaga, Tatyana ^a   Han, Yong Hae ^a   Balimane, Praveen ^a   Marathe, Punit ^a   Rodrigues, A David ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865180954     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0840-7_23     Document Type: Chapter

References (154)

1. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouet S, Morel F, Guguen-Guillouzo C and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83
2. Ayrton A and Morgan P (2008) Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38:676-708
3. Bachmann KA (2006) Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 7:1-14
4. Backman JT, Luurila H, Neuvonen M and Neuvonen PJ (2005) Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78:154-167
5. Balimane PV, Han YH and Chong S (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. Aaps J 8:E1-E13
6. Benet LZ, Amidon GL, Barends DM, Lennernas H, Polli JE, Shah VP, Stavchansky SA and Yu LX (2008) The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 25:483-488
7. Benet LZ, Cummins CL and Wu CY (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4:393-398
8. Bi YA, Kazolias D and Duignan DB (2006) Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos 34:1658-1665
9. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J and Wrighton SA (2003) The conduct of in vitro and in vivo drugdrug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832
10. Brown HS, Galetin A, Hallifax D and Houston JB (2006) Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45:1035-1050
11. Brown HS, Ito K, Galetin A and Houston JB (2005) Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508-518
12. Cascio SM (2001) Novel strategies for immortalization of human hepatocytes. Artif Organs 25:529-538
13. Chiou WL, Chung SM and Wu TC (2000) Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903-905
14. Crespi CL and Miller VP (1999) The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Ther 84:121-131
15. Crespi CL, Miller VP and Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188-190
16. Down MJ, Arkle S and Mills JJ (2007) Regulation and induction of CYP3A11, CYP3A13 and CYP3A25 in C57BL/6 J mouse liver. Arch Biochem Biophys 457:105-110
17. Ek M, Soderdahl T, Kuppers-Munther B, Edsbagge J, Andersson TB, Bjorquist P, Cotgreave I, Jernstrom B, Ingelman-Sundberg M and Johansson I (2007) Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 74:496-503
18. El-Sankary W, Gibson GG, Ayrton A and Plant N (2001) Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29:1499-1504
19. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708
20. Fayer JL, Zannikos PN, Stevens JC, Luo Y, Sidhu R and Kirkesseli S (2001) Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity. J Clin Pharmacol 41:305-316
21. FDA (2006) FDA Draft Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling, in.
22. Fontana E, Dansette PM and Poli SM (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413-454
23. Galetin A, Burt H, Gibbons L and Houston JB (2006) Prediction of time-dependent CYP3A4 drugdrug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175
24. Galetin A, Hinton LK, Burt H, Obach RS and Houston JB (2007) Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8:685-693
25. Gonzalez FJ and Yu AM (2006) Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 46:41-64
26. Goodwin B, Hodgson E and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339
27. Greenblatt DJ, Von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL and Shader RI (2000) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136
28. Grime K and Riley RJ (2006) The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 7:251-264
29. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C and Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99:15655-15660
30. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F and Guguen-Guillouzo C (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168:66-73
31. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18
32. Hagenbuch B and Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653-665
33. Hahn WC (2002) Immortalization and transformation of human cells. Mol Cells 13:351-361
34. Hamilton GA, Jolley SL, Gilbert D, Coon DJ, Barros S and Le Cluyse EL (2001) Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 306:85-99
35. Harmsen S, Meijerman I, Beijnen JH and Schellens JH (2007) The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat Rev 33:369-380
36. Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG and Kim RB (2008) A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab Dispos 36:500-507
37. Hewitt NJ, De Kanter R and Le Cluyse E (2007a) Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry-do they comply with FDA recommendations?. Chem Biol Interact 168:51-65
38. Hewitt NJ and Hewitt P (2004) Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 34:243-256
39. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, Le Cluyse E, Groothuis GM and Hengstler JG (2007b) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234
40. Hidalgo I (2001) Assessing the absorption of new pharmaceuticals. Curr Topics Med Chem 1:385-401
41. Hinton LK, Galetin A and Houston JB (2008) Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 25:1063-1074
42. Hirano M, Maeda K, Shitara Y and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146
43. Honkakoski P, Sueyoshi T and Negishi M (2003) Drug-activated nuclear receptors CAR and PXR. Ann Med 35:172-182
44. Hsiao P, Bui T, Ho RJ and Unadkat JD (2007) In vitro to in vivo prediction of p-glycoprotein based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos 34:786-792.
45. Hsu A, Granneman GR, Cao G, Carothers L, El-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E and Leonard JM (1998) Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 63:453-464
46. Huang C, Zheng M, Yang Z, Rodrigues AD and Marathe P (2008) Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?. Pharm Res 25:713-726
47. Huang SM, Lesko LJ and Williams RL (1999) Assessment of the quality and quantity of drugdrug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol 39:1006-1014
48. Ito K, Brown HS and Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486
49. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412
50. Jaakkola T, Backman JT, Neuvonen M, Niemi M and Neuvonen PJ (2006) Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol 62:503-509
51. Jones-Bolin S, Zhao H, Hunter K, Klein-Szanto A and Ruggeri B (2006) The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol Cancer Ther 5:1744-1753
52. Kai H, Shibuya K, Wang Y, Kameta H, Kameyama T, Tahara-Hanaoka S, Miyamoto A, Honda S, Matsumoto I, Koyama A, Sumida T and Shibuya A (2006) Critical role of M. tuberculosis for dendritic cell maturation to induce collagen-induced arthritis in H-2b background of C57BL/6 mice. Immunology 118:233-239
53. Kajosaari LI, Jaakkola T, Neuvonen PJ and Backman JT (2006) Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 62:217-223
54. Kanamitsu S, Ito K and Sugiyama Y (2000) Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336-343
55. Kanazu T, Yamaguchi Y, Okamura N, Baba T and Koike M (2004) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391-402
56. Kariv I, Fereshteh MP and Oldenburg KR (2001) Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J Biomol Screen 6:91-99
57. Keogh JP and Kunta JR (2006) Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27:543-554
58. Kerns E, Di L, Petusky S, Farris M, Ley R and Jupp P (2004) Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharma Sci 93:1440-1453
59. Kiang TK, Ensom MH and Chang TK (2005) UDP-glucuronosyltransferases and clinical drugdrug interactions. Pharmacol Ther 106:97-132
60. Kim KA, Park PW, Kim KR and Park JY (2007) Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. Br J Clin Pharmacol 63:339-345
61. Kliewer SA, Goodwin B and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702
62. Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N and Sugiyama Y (2000) Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos 28:475-481
63. Lam JL, Okochi H, Huang Y and Benet LZ (2006) In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporterenzyme interplay. Drug Metab Dispos 34:1336-1344
64. Lau YY, Huang Y, Frassetto L and Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204
65. Le Cluyse E, Madan A, Hamilton G, Carroll K, De Haan R and Parkinson A (2000) Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J Biochem Mol Toxicol 14:177-188
66. Le Cluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S and Richert L (2005) Isolation and culture of primary human hepatocytes. Methods Mol Biol 290:207-229
67. Lee CM and Farde L (2006) Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 27:310-316
68. Li P, Callery PS, Gan LS and Balani SK (2007) Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos 35:1023-1031
69. Lin J and Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics. Clin Pharmacokinet 42:59-98
70. Lin JH (2007) Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3:81-92
71. Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390
72. Lin JH and Pearson PG (2002) Prediction of metabolic drug interactions: quantitative or qualitative?, in Drug-Drug Interactions (Rodrigues AD ed) pp 415-438, Marcel Dekker, Basel, Switzerland.
73. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, Le Cluyse E and Gan LS (2002) CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 30:795-804
74. Luo G, Garner CE, Xiong H, Hu H, Richards LE, Brouwer KL, Duan J, Decicco CP, Maduskuie T, Shen H, Lee FW and Gan LS (2007) Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy) phenyl]-2-oxopyrr olidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study. Drug Metab Dispos 35:835-840
75. Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, Le Cluyse E, Solon E, Brennan JM, Benedek IH, Jolley S, Gilbert D, Wang L, Lee FW and Gan LS (2003) Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 31:1170-1175
76. Lyon K, Faris R, Liu J, Snyder J, Brobst D, Lichti K, Staudinger J, Czerwinski M, Toren P and Parkinson A (2005) Improving lot-to-lot variability and dynamic range of CYP3A4 indution in immortalized human hepatocytes (Fa2N-4 cells), in Internation Society for the Study of Xenobiotics, Maui, HI.
77. Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR and Gonzalez FJ (2007) The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35:194-200
78. Madan A, Usuki E, Burton LA, Ogilvie BW and Parkinson A (2002) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs, in Drug-drug interactions (Rodrigues AD ed) pp 217-294, Marcel Dekker, Inc, Basel-Switzerland.
79. Mandal PK (2005) Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Comp Physiol [B] 175:221-230
80. Marathe PH and Rodrigues AD (2006) In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. CurrDrug Metab 7:687-704
81. Marion TL, Leslie EM and Brouwer KL (2007) Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol Pharm 4:911-918
82. Matheny C, Lamb M, Brouwer K and Pollak G (2001) Pharmacokinetic and pharmacodynamic implications of P-gp modulation. Pharmacotherapy 21:778-796
83. Medina-Diaz IM, Arteaga-Illan G, De Leon MB, Cisneros B, Sierra-Santoyo A, Vega L, Gonzalez FJ and Elizondo G (2007) Pregnane X receptor-dependent induction of the CYP3A4 gene by o, p'-1, 1, 1, -trichloro-2, 2-bis (p-chlorophenyl) ethane. Drug Metab Dispos 35:95-102
84. Medina-Diaz IM and Elizondo G (2005) Transcriptional induction of CYP3A4 by o, p'-DDT in HepG2 cells. Toxicol Lett 157:41-47
85. Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T and Haefeli WE (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 80:126-135
86. Miller VP, Stresser DM, Blanchard AP, Turner S and Crespi CL (2000) Fluorometric highthroughput screening for inhibitors of cytochrome P450. Ann N Y Acad Sci 919:26-32
87. Mills JB, Rose KA, Sadagopan N, Sahi J and De Morais SM (2004) Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 309:303-309
88. Miners JO, Smith PA, Sorich MJ, McKinnon RA and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25
89. Naritomi Y, Teramura Y, Terashita S and Kagayama A (2004) Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab Pharmacokinet 19:55-61
90. Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787-802
91. Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF and Eichelbaum M (2006) Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genom 16:565-568
92. Nishimura M, Koeda A, Suganuma Y, Suzuki E, Shimizu T, Nakayama M, Satoh T, Narimatsu S and Naito S (2007) Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab Pharmacokinet 22:178-186
93. Obach RS (2001) The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discovery Dev 4:36-44
94. Obach RS, Walsky RL and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255
95. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592
96. Ogasawara A, Kume T and Kazama E (2007) Effect of oral ketoconazole on intestinal firstpass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410-418
97. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197
98. Ohno Y, Hisaka A and Suzuki H (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46:681-696
99. Ozbal CC, La Marr WA, Linton JR, Green DF, Katz A, Morrison TB and Brenan CJ (2004) High throughput screening via mass spectrometry: a case study using acetylcholinesterase. Assay Drug Dev Technol 2:373-381
100. Poirier A, Funk C, Lave T and Noe J (2007) New strategies to address drug-drug interactions involving OATPs. Curr Opin Drug Discovery Dev 10:74-83
101. Polli J, Jerrett J, Studenberg J, Humphreys J, Dennis S, Brower K and Wooley J (1999) Role of P-gp on CNS disposition of amprenavir, an HIV protease inhibitor. Pharma Res 16:1206-1212
102. Polli J, Wring S, Humphreys J, Huang L, Morgan J, Webster L and Serabjit-Singh C (2001) Rational use of in vitro P-gp assays in drug discovery. J Pharmacol Exp Ther 299:620-628
103. Preskorn SH and Magnus RD (1994) Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 30:251-259
104. Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B and Lin JH (2006) In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34:1546-1555
105. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG and Baillie TA (2002) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051
106. Rencurel F, Stenhouse A, Hawley SA, Friedberg T, Hardie DG, Sutherland C and Wolf CR (2005) AMP-activated protein kinase mediates phenobarbital induction of CYP2B gene expression in hepatocytes and a newly derived human hepatoma cell line. J Biol Chem 280:4367-4373
107. Riley RJ (2001) The potential pharmacological and toxicological impact of P450 screening. Curr Opin Drug Discov Dev 4:45-54
108. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS and De Morais SM (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748
109. Rodrigues AD (2007) Prioritization of clinical drug inteaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. Drug Metab Lett 1:31-35
110. Rodrigues AD, Winchell GA and Dobrinska MR (2001) Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 41:368-373
111. Rostami-Hodjegan A and Tucker G (2004) "In silico" simulations to assess the "in vivo" consequences of "in vitro" metabolic drug-drug interactions. Drug Discovery Today 1:441-448
112. Rowland M and Matin SB (1973) Kinetics of drug-drug interactions. J Pharmacokinet Biopharma 1:553-567
113. Roymans D, Annaert P, Van Houdt J, Weygers A, Noukens J, Sensenhauser C, Silva J, Van Looveren C, Hendrickx J, Mannens G and Meuldermans W (2005) Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab Dispos 33:1004-1016
114. Runge D, Michalopoulos GK, Strom SC and Runge DM (2000) Recent advances in human hepatocyte culture systems. Biochem Biophys Res Commun 274:1-3
115. Schehrer L, Regan JD and Westendorf J (2000) UDS induction by an array of standard carcinogens in human and rodent hepatocytes: effect of cryopreservation. Toxicology 147:177-191
116. Schrag ML, Cui D, Rushmore TH, Shou M, Ma B and Rodrigues AD (2004) Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab Dispos 32:1299-1303
117. Schwenk M (1980) Transport systems of isolated hepatocytes. Studies on the transport of biliary compounds. Arch Toxicol 44:113-126
118. Shiau AK, Massari ME and Ozbal CC (2008) Back to basics: label-free technologies for small molecule screening. Comb Chem High Throughput Screen 11:231-237
119. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283
120. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K and Rodrigues AD (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375-388
121. Sinz MW and Kim S (2006) Stem cells, immortalized cells and primary cells in ADMET assays. Drug Discovery Today 3:79-85
122. Smith NF, Figg WD and Sparreboom A (2005) Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 1:429-445
123. Soars MG, McGinnity DF, Grime K and Riley RJ (2007) The pivotal role of hepatocytes in drug discovery. Chem Biol Interact 168:2-15
124. Stanley LA, Horsburgh BC, Ross J, Scheer N and Wolf CR (2006) PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38:515-597
125. Surveillance BCD (1972) Adverse drug interactions. J Am Med Assoc 220:1238-1239
126. Suzuki H and Sugiyama Y (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12
127. Synold TW, Dussault I and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590
128. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T and Yoshizato K (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912
129. Tirona RG and Kim RB (2005) Nuclear receptors and drug disposition gene regulation. J Pharm Sci 94:1169-1186
130. Trubetskoy OV, Gibson JR and Marks BD (2005) Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 10:56-66
131. Tucker GT, Houston JB and Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 70:103-114
132. Venkatakrishnan K, Obach RS and Rostami-Hodjegan A (2007) Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37:1225-1256
133. Vermeir M, Annaert P, Mamidi RN, Roymans D, Meuldermans W and Mannens G (2005) Cellbased models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol 1:75-90
134. Vignati LA, Bogni A, Grossi P and Monshouwer M (2004) A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Toxicology 199:23-33
135. Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS and Shader RI (1994) In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222-1227
136. Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379
137. Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR and Mani S (2007) Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res 13:2488-2495
138. Wang YH, Jones DR and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266
139. White RE (2000) High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 40:133-157
140. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208
141. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23
142. Xie W and Evans RM (2002) Pharmaceutical use of mouse models humanized for the xenobiotic receptor. Drug Discovery Today 7:509-515
143. Yamamoto T, Suzuki A and Kohno Y (2004) High-throughput screening for the assessment of timedependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 34:87-101
144. Yan Z, Rafferty B, Caldwell GW and Masucci JA (2002) Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Eur J Drug Metab Pharmacokinet 27:281-287
145. Yao C and Levy RH (2002) Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 91:1923-1935
146. Youdim KA, Lyons R, Payne L, Jones BC and Saunders K (2008) An automated, high-throughput, 384 well cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. J Pharm Biomed Anal 48:92-99
147. Youdim KA, Tyman CA, Jones BC and Hyland R (2007) Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay. Drug Metab Dispos 35:275-282
148. Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203-1211
149. Zhang H, Davis CD, Sinz MW and Rodrigues AD (2007a) Cytochrome P450 reactionphenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687
150. Zhang H, Zhang D, Li W, Yao M, D'Arienzo C, Li YX, Ewing WR, Gu Z, Zhu Y, Murugesan N, Shyu WC and Humphreys WG (2007b) Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. Drug Metab Dispos 35:795-805
151. Zheng HX, Huang Y, Frassetto LA and Benet LZ (2009) Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85:78-85
152. Zhou C, Poulton EJ, Grun F, Bammler TK, Blumberg B, Thummel KE and Eaton DL (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220-229
153. Zhu Z, Kim S, Chen T, Lin JH, Bell A, Bryson J, Dubaquie Y, Yan N, Yanchunas J, Xie D, Stoffel R, Sinz M and Dickinson K (2004) Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533-540
154. Zientek M, Miller H, Smith D, Dunklee MB, Heinle L, Thurston A, Lee C, Hyland R, Fahmi O and Burdette D (2008) Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 58:206-214